AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Stock icons drug discovery1/8/2024 ![]() While it’s counted as revenue, it sits on the balance sheet as an asset, albeit one that’s not likely to be very liquid. Then there’s the $4.6 million in revenues recorded for the first half of 2021 which consisted of 13% share ownership in a Chinese firm called GT Apeiron Therapeutics. So far, most of their revenues are coming from their relationship with Celgene.ĭuring the periods ending December 31, 20, 69% and 83% of our revenue, respectively, related to the recognition of the Celgene up-front payments in line with our progress towards delivering up to three clinical candidate compounds. From collaborations to joint ventures, the business model quickly becomes so complex that it’s hard to fathom how anyone can keep track of what’s going on. Each relationship Exscientia has comes with its own terms. There are two revenue streams – service fees and licensing fees – from which there can be four types of payments upfront payments, research funding, milestone payments, and opt-in payments. While Exscientia’s revenues may appear to be starting out stable, there’s loads of volatility bubbling under the surface. If a software- as- a– service ( SaaS) business model is to be rewarded for consistency and predictability, then a business model with unpredictable revenue streams should be penalized. That’s an easy value proposition to understand, but the accompanying business model is anything but. Once there’s a drug candidate, it then needs to proceed through the FDA drug approval process like any other. As seen below, Exscientia reduces the time it takes to go from target to candidate by 70%. All that money was used to build an AI-powered design platform known as Centaur Chemist which combines the power of machine learning with the knowledge of human chemists to discover drugs faster. Exscientia Stockįounded in 2012, Oxford’s own Exscientia raised $374.4 million in disclosed funding from a slew of investors including names like Softbank, BlackRock, Celgene, Bristol Myers Squibb, and Sir William of Gates. startup called Exscientia which recently filed for an initial public offering ( IPO). Earlier this year, we wrote about 7 Companies Using AI for Drug Discovery, one of which was a U.K. In past articles we’ve written extensively about AI drug discovery companies using techniques like computational drug discovery techniques. If an AI algorithm can master the game of Go, it can probably help us discover better drugs. ![]() Four AI Drug Discovery Stocks Company NameĪrtificial intelligence algorithms are great for solving complex problems using lots of data. Today, we’re going to look at four different publicly traded companies that are using AI to improve the drug discovery process. Without revenues, it’s practically impossible to properly examine a business model, which is why we don’t invest pre-revenue. One way to break down the complexity of a company is by examining their business model. If, as risk-averse investors, we adhere to Warren Buffett’s adage of only investing in what we understand, this puts us in a difficult position. When you start to apply AI to complex domains like drug discovery, there’s a snowball’s chance in hell your average retail investor will understand what’s happening under the hood. ![]() A technology like artificial intelligence (AI) is extraordinarily complex to begin with.
0 Comments
Read More
Leave a Reply. |